Back to mobile site

Baird Reiterates Neutral Rating on Regeneron Pharma (REGN)

September 24, 2024 5:30 AM EDT Send to a Friend
Baird analyst Brian Skorney reiterated a Neutral rating and $940.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst comments "Incrementally ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login